pharmaceutic

Innovative Small Molecules

We focus on value creation through the design of novel chemical entities that modulate well validated targets in fibrosis and cancer.

Organ Restrictive Compounds

Our strategy involves the development of organ-restricted compounds to maximize the potential of local TGF-β inhibition while sparing target-related toxicities, making TGF-β inhibitors a reality for patients.

Well Validated Targets

We aim at harnessing the potential of well validated targets. Our current focus is the modulation of the TGF-β pathway, a key regulator of fibrosis development and immunosuppression.